|
Guideline-based indicators for adult patients with myelodysplastic syndromes |
Aug 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure |
Jul 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria |
Jun 2023 |
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes |
Oct 2019 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients |
Nov 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome |
Apr 2023 |
Blood Cancer |
Myelodysplastic Syndromes (MDS) |
|
Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria |
Mar 2021 |
Blood cells, molecules and diseases |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review |
Jul 2023 |
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
|
Current and emerging strategies for management of myelodysplastic syndromes |
Dec 2020 |
Blood reviews |
Myelodysplastic Syndromes (MDS) |
